178 related articles for article (PubMed ID: 36859777)
21. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
22. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.
Shekhar R; Naseem S; Binota J; Varma N; Malhotra P
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):231-239. PubMed ID: 33217360
[TBL] [Abstract][Full Text] [Related]
23. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
24. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.
Insuasti-Beltran G; Gale JM; Wilson CS; Foucar K; Czuchlewski DR
Arch Pathol Lab Med; 2015 Aug; 139(8):1035-41. PubMed ID: 26230596
[TBL] [Abstract][Full Text] [Related]
25. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
[TBL] [Abstract][Full Text] [Related]
26. Detection of the MYD88
Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
[TBL] [Abstract][Full Text] [Related]
27. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Okoshi Y; Goshima Y; Yanagimoto S; Nakamoto-Matsubara R; Sato T; Noguchi M; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Chiba S
Br J Haematol; 2017 May; 177(3):492-494. PubMed ID: 27161435
[No Abstract] [Full Text] [Related]
28. A rapid genotyping panel for detection of primary central nervous system lymphoma.
Gupta M; Burns EJ; Georgantas NZ; Thierauf J; Nayyar N; Gordon A; Jones SS; Pisapia M; Sun Y; Burns RP; Velarde J; Jordan JT; Frigault MJ; Nahed BV; Jones PS; Barker FG; Curry WT; Gupta R; Batchelor TT; Romero JM; Brastianos PK; Marble HD; Martinez-Lage M; Tateishi K; Lennerz JK; Dietrich J; Cahill DP; Carter BS; Shankar GM
Blood; 2021 Aug; 138(5):382-386. PubMed ID: 33735913
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
[TBL] [Abstract][Full Text] [Related]
30. Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation.
Wang CZ; Lin J; Qian J; Shao R; Xue D; Qian W; Xiao GF; Deng ZQ; Yang J; Li Y; Chen XX
Clin Biochem; 2013 Mar; 46(4-5):385-7. PubMed ID: 23178471
[TBL] [Abstract][Full Text] [Related]
31. Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy.
Balikov DA; Hu K; Liu CJ; Betz BL; Chinnaiyan AM; Devisetty LV; Venneti S; Tomlins SA; Cani AK; Rao RC
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576156
[TBL] [Abstract][Full Text] [Related]
32. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.
Nishimura N; Takeuchi K; Asaka R; Tuyama N; Inoue N; Kusano Y; Mishima Y; Yokoyama M; Terui Y
Leuk Res; 2020 Oct; 97():106426. PubMed ID: 32781214
[TBL] [Abstract][Full Text] [Related]
33. MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.
Miserocchi E; Ferreri AJM; Giuffrè C; Cangi MG; Francaviglia I; Calimeri T; Ponzoni M; Pecciarini L; Bandello FM; Modorati GM
Retina; 2019 Apr; 39(4):679-684. PubMed ID: 30204732
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L
Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
[TBL] [Abstract][Full Text] [Related]
35. Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction.
Shi H; Zhou X; Chen B; Xiao J; Li Y; Zhou X; Zhou Q; Chen K; Wang Q
Ocul Immunol Inflamm; 2021 Apr; 29(3):448-455. PubMed ID: 31603365
[No Abstract] [Full Text] [Related]
36. MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring : ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation.
Drandi D; Ferrante M; Borriero M; Ferrero S
Methods Mol Biol; 2023; 2621():57-72. PubMed ID: 37041440
[TBL] [Abstract][Full Text] [Related]
37. Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases.
Iriyama C; Murate K; Iba S; Okamoto A; Goto N; Yamamoto H; Kato T; Mihara K; Miyama T; Hattori K; Kajiya R; Okamoto M; Mizutani Y; Yamada S; Tsukamoto T; Hirose Y; Mutoh T; Watanabe H; Tomita A
Cancer Med; 2023 Aug; 12(16):16972-16984. PubMed ID: 37501501
[TBL] [Abstract][Full Text] [Related]
38. Characterization of genomic alterations in primary central nervous system lymphomas.
Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
[TBL] [Abstract][Full Text] [Related]
39. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.
Poulain S; Boyle EM; Roumier C; Demarquette H; Wemeau M; Geffroy S; Herbaux C; Bertrand E; Hivert B; Terriou L; Verrier A; Pollet JP; Maurage CA; Onraed B; Morschhauser F; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
Br J Haematol; 2014 Nov; 167(4):506-13. PubMed ID: 25160558
[TBL] [Abstract][Full Text] [Related]
40. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.
Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F
Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
